Innovative vaccines for a healthier world

We want to transform healthcare by developing novel vaccines that are life-saving and improving quality of life around the world.

Interview with CEO Bent Frandsen

Explore ExpreS2ion Biotechnologies, an innovator within biotechnology.
In a detailed interview, CEO Bent Frandsen outlines our progress in developing innovative vaccines for a healthier world.
Uncover the substantial impact of our pioneering work and the compelling reasons to invest.
Engage with us as we lead in transformative solutions through the advanced capabilities of ExpreS2ion Biotechnologies.
 

Next Event

  • Thu
    30
    May
    2024

    Biostock Global Forum

    11:00Medicon Village in Lund, Sweden

    Bent Frandsen will present at The Global Forum 2024, an event focusing on international expansion, partnerships, and capital attraction. The forum includes keynotes, panels, and company presentations, providing insights into market conditions, cultural differences, and regulatory pathways. It offers networking opportunities with experts and investors from Europe, the US, and Asia. Check the official website for registration and updates.

Latest News

ExpreS2ion announces financial results for the first quarter of 2024

Hørsholm, Denmark, 16 May 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first quarter financial results for 2024. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion to present in spring investor events

Hørsholm, Denmark, 15 May 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in upcoming investor events.

Read more

ExpreS2ion annual report for 2023 published

Hørsholm, Denmark, 8 May 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's annual report for the financial year 2023 is published. The annual report is available as an attachment and on ExpreS2ion's website at the following address (https://investor.expres2ionbio.com/reports/).

Read more